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Prior CABG
(n250)
No Prior
CABG
(n3292) P-Value
Culprit SVG
(n81)
Native
Culprit
(n99)
No Culprit
(n57) P-Value
Age (Yrs),
mean(SD)
69.4 	/
12.0
62.0 	/
14.3
0.001 68.5 	/
11.4
68.7
	/
11.6
69.2 	/
12.4
0.90/
0.95
Male, (%) 204 (81.6) 2324
(70.6)
0.001 67 (82.7) 83
(83.8)
45 (79.0) 0.84/
0.74
BMI, mean(SD) 28.6 	/
5.7
28.9 	/
6.0
0.40 28.6 	/
4.7
28.5
	/
6.0
28.8 	/
6.7
0.90/
0.97
OOHCA, (%) 15 (6.0) 296 (9.0) 0.11 3 (3.7) 6 (6.1) 4 (7.0) 0.47/
0.67
Shock Pre-PCI,
(%)
20 (8.0) 279 (8.5) 0.79 11 (13.6) 4 (4.0) 4 (7.0) 0.021/
0.061
History of
smoking, (%)
147 (59.5) 1995
(61.0)
0.64 52 (64.2) 47
(48.0)
42 (73.7) 0.03/
0.004
Current Smoker-,
(%)
47 (32.0) 1233
(61.8)
0.001 17 (32.7) 18
(38.3)
10 (23.8) 0.56/
0.34
Diabetes, (%) 89 (35.7) 518 (15.8) 0.001 29 (35.8) 30
(30.6)
23 (40.4) 0.46/
0.46
EF (%), mean(SD) 45.3 	/
14.4
47.4 	/
13.3
0.020 45.0 	/
13.8
45.4
	/
14.6
48.2 	/
14.3
0.82/
0.42
Killip Class 0.98 0.061/
0.15
0/1, (%) 218 (87.2) 2867
(87.1)
67 (82.7) 91
(91.9)
48 (84.2)
2/4, (%) 32 (12.8) 423 (12.9) 14 (17.3) 8 (8.1) 9 (15.8)
Intervention
Done, (%)
169 (67.6) 2622
(79.8)
0.001 71 (87.7) 94
(95.0)
2 (3.5) 0.078/
0.001
D2B (mins),
median (25th,
75th percentile)
98 (74,
124)
95 (74,
124)
0.35 95 (75,
119)
98
(75,
119)
107 (84,
130.5)
0.87**/
0.27**
Death In Hospital,
(%)
12 (4.8) 165 (5.0) 0.88 6 (7.4) 2 (2.0) 2 (3.5) 0.081/
0.19
Death at 30
Days, (%)
12 (4.8) 189 (5.7) 0.54 6 (7.4) 2 (2.0) 2 (3.5) 0.081/
0.19
Death at 1 Year,
(%)
27 (10.8) 295 (9.0) 0.33 10 (12.4) 7 (7.1) 4 (7.0) 0.23/0.40
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Background: Several clinical and angiographic scores have been proposed for the
prediction of the outcome of patients with myocardial infarction undergoing primary
percutaneous coronary angiography (PCI). The aim of this study was to assess the ability
of Clinical Syntax Score (CSS) for predicting outcome late after successful primary PCI.
Methods: 345 consecutive patients that underwent successful primary PCI due to STEMI
in our hospital were recruited out of 361 primary PCIs. CSS was calculated for each
patient as previously described. The patients were followed by outpatient visit or
telephone for 2 years. Endpoints included all-cause death, cardiac death, repeat revascu-
larization (RR), stent thrombosis (ST) and major adverse cardiac event (MACE), defined
as the composite of death, myocardial infarction, or target vessel revascularization.
Results: The median follow-up period was 476 days (mean 4965 days). Table 1
presents the 2-year outcomes according to CSS tertile, while the figure shows Kaplan-
Meier curves for freedom from cardiac death and MACE, respectively, stratified by CSS
tertile. CSS score was higher in patients with death or cardiovascular death, RR and
MACE.
CSS LOW
(n117)
CSS MID
(n109)
CSS HIGH
(n119) p-value
Total Death 6 (5.1%) 14 (12.8%) 22 (18.4%) 0.007
Cardiac death 1(0.8%) 5 (4.5%) 13 (10.9%) 0.02
ST 0 (0%) 0 (0%) 2(1.6%) 0.14
RR 5 (4.2%) 4(3.6%) 15 (12.6%) 0.01
MACE 5 (4.2%) 6 (5.5%) 20(16.8%) 0.001
Conclusions: CSS is a reliable tool for assessing outcome after successful PCI in patients
with myocardial infarction and successful primary PCI.
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Background: There were no published data regarding the clinical efficacy and safety of
second generation drug-eluting stent (zotarolimus-eluting stent with biolinx polymer,
ZES-BP, Endeavor resolute) following primary percutaneous coronary intervention (PCI)
in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of
zotarolimus-eluting stent with biolinx polymer versus to 1st generation (sirolimus-eluting
stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting
stent, ZES and everolimus-eluting stent, EES) drug-eluting stents(DES) for the treatment
of STEMI.
Methods: A prospective, open-labeled, multi-center cohort has been performed. The
primary endpoint was major adverse cardiac event (MACE): the composite of cardiac
death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1
year. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 975 patients (ZES-BP178, EES197, ZES203, SES203,
PES194) were analyzed. One-year MACE were 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in
ZES-BP, EES, ZES, SES and PES group, respectively (pns). Cardiac death were 2.3%,
1.0%, 2.5%, 1.5% and 1.0% in ZES-BP, EES, ZES, SES and PES group, respectively
(pns).
Conclusions: Compared to 1st and 2nd generation DES (SES and PES, ZES), EES and
ZES-BP showed similar one-year clinical outcomes in terms of MACE in patients with
STEMI following primary PCI and no stent thrombosis.
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Background: Recent studies suggest door in-door out (DIDO) time may predict
outcomes in ST-elevation myocardial infarction (STEMI) patients transferred from a
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